Global Lung Transplant Rejection Market

Lung Transplant Rejection Comprehensive Study by Type (Cellular Rejection, Antibody-Mediated Rejections, Allograft Rejection, Acute Rejections, Chronic Rejections), Application (Lung Transplant Patients) Players and Region - Global Market Outlook to 2030

Lung Transplant Rejection Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Lung Transplant Rejection
Lung transplant is the only option for patients with end-stage lung disease, conditions generated by emphysema, pulmonary fibrosis, cystic fibrosis, and other lung diseases. Lung transplant rejection is the response of the body to defend itself from a foreign substance such as bacteria, in lung transplant case rejection is a process in which the body’s immune system attacks on the lung transplanted lung by recognizing it to be different from own tissues.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Lung Transplant Rejection market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Lung Transplant Rejection Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Lung Transplant Rejection market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbVie (United States), Arthrex (United States), Zimmer Biomet (United States), Medtronic (Ireland), Novartis (Switzerland), Stryker (United States), BioLifeSolutions (United States), Teva Pharmaceuticals (Israel), Veloxis Pharmaceuticals (Denmark) and Gleneagles global hospitals (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pfizer Inc. (United States), Allergan (Ireland) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Lung Transplant Rejection market by Type (Cellular Rejection, Antibody-Mediated Rejections, Allograft Rejection, Acute Rejections and Chronic Rejections), Application (Lung Transplant Patients) and Region.



On the basis of geography, the market of Lung Transplant Rejection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Increase in Chronic Rejection in Lung Transplant

Market Growth Drivers:
Rise in Patients with Patients with End-Stage Lung Disease and Other Lung Diseases

Challenges:
Lung Transplant Rejection Is Develop Silently Without Any Obvious System, Which Become Challenge for Defining Lung Transplant at Early Stage

Restraints:
High cost of lung transplant.

Market Leaders and their expansionary development strategies
In February 2019, Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announced interim results from the Company’s Phase 2 trial of intravenous Alpha-1 Antitrypsin (IV-AAT) for the prevention of lung transplant rejection following one year of treatment for all patients.
In Jan 2019, Researcher Created A Blood Test To Detect Chronic Lung Transplant Rejection, Which Is Severe And Irreversible Without Getting Outward Signs. These Research Has Funded By the National Institutes of Health (NIH) Segment National Heart, Lung, and Blood Institute (NHLBI). Additionally, In Feb 2019, Researchers At Washington University School Of Medicine Has Discovered A Clues To Deadly Form Of Rejection Called Antibody-Mediated Rejection.


Key Target Audience
Manufacturers Suppliers and Distributors, Venture Capitalists and Private Equity Firms, New Entrants/Investors, Strategic Business Planners, Government Regulatory, Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Cellular Rejection
  • Antibody-Mediated Rejections
  • Allograft Rejection
  • Acute Rejections
  • Chronic Rejections
By Application
  • Lung Transplant Patients
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Patients with Patients with End-Stage Lung Disease and Other Lung Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lung Transplant Rejection Is Develop Silently Without Any Obvious System, Which Become Challenge for Defining Lung Transplant at Early Stage
    • 3.4. Market Trends
      • 3.4.1. Increase in Chronic Rejection in Lung Transplant
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lung Transplant Rejection, by Type, Application and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lung Transplant Rejection (Value)
      • 5.2.1. Global Lung Transplant Rejection by: Type (Value)
        • 5.2.1.1. Cellular Rejection
        • 5.2.1.2. Antibody-Mediated Rejections
        • 5.2.1.3. Allograft Rejection
        • 5.2.1.4. Acute Rejections
        • 5.2.1.5. Chronic Rejections
      • 5.2.2. Global Lung Transplant Rejection by: Application (Value)
        • 5.2.2.1. Lung Transplant Patients
      • 5.2.3. Global Lung Transplant Rejection Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Lung Transplant Rejection: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Arthrex (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Zimmer Biomet (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medtronic (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Stryker (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioLifeSolutions (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceuticals (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Veloxis Pharmaceuticals (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Gleneagles global hospitals (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lung Transplant Rejection Sale, by Type, Application and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lung Transplant Rejection (Value)
      • 7.2.1. Global Lung Transplant Rejection by: Type (Value)
        • 7.2.1.1. Cellular Rejection
        • 7.2.1.2. Antibody-Mediated Rejections
        • 7.2.1.3. Allograft Rejection
        • 7.2.1.4. Acute Rejections
        • 7.2.1.5. Chronic Rejections
      • 7.2.2. Global Lung Transplant Rejection by: Application (Value)
        • 7.2.2.1. Lung Transplant Patients
      • 7.2.3. Global Lung Transplant Rejection Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lung Transplant Rejection: by Type(USD Million)
  • Table 2. Lung Transplant Rejection Cellular Rejection , by Region USD Million (2018-2023)
  • Table 3. Lung Transplant Rejection Antibody-Mediated Rejections , by Region USD Million (2018-2023)
  • Table 4. Lung Transplant Rejection Allograft Rejection , by Region USD Million (2018-2023)
  • Table 5. Lung Transplant Rejection Acute Rejections , by Region USD Million (2018-2023)
  • Table 6. Lung Transplant Rejection Chronic Rejections , by Region USD Million (2018-2023)
  • Table 7. Lung Transplant Rejection: by Application(USD Million)
  • Table 8. Lung Transplant Rejection Lung Transplant Patients , by Region USD Million (2018-2023)
  • Table 9. South America Lung Transplant Rejection, by Country USD Million (2018-2023)
  • Table 10. South America Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 11. South America Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 12. Brazil Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 13. Brazil Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 14. Argentina Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 15. Argentina Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 16. Rest of South America Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 17. Rest of South America Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 18. Asia Pacific Lung Transplant Rejection, by Country USD Million (2018-2023)
  • Table 19. Asia Pacific Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 20. Asia Pacific Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 21. China Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 22. China Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 23. Japan Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 24. Japan Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 25. India Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 26. India Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 27. South Korea Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 28. South Korea Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 29. Taiwan Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 30. Taiwan Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 31. Australia Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 32. Australia Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 33. Rest of Asia-Pacific Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 34. Rest of Asia-Pacific Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 35. Europe Lung Transplant Rejection, by Country USD Million (2018-2023)
  • Table 36. Europe Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 37. Europe Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 38. Germany Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 39. Germany Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 40. France Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 41. France Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 42. Italy Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 43. Italy Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 44. United Kingdom Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 45. United Kingdom Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 46. Netherlands Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 47. Netherlands Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 48. Rest of Europe Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 49. Rest of Europe Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 50. MEA Lung Transplant Rejection, by Country USD Million (2018-2023)
  • Table 51. MEA Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 52. MEA Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 53. Middle East Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 54. Middle East Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 55. Africa Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 56. Africa Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 57. North America Lung Transplant Rejection, by Country USD Million (2018-2023)
  • Table 58. North America Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 59. North America Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 60. United States Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 61. United States Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 62. Canada Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 63. Canada Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 64. Mexico Lung Transplant Rejection, by Type USD Million (2018-2023)
  • Table 65. Mexico Lung Transplant Rejection, by Application USD Million (2018-2023)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Lung Transplant Rejection: by Type(USD Million)
  • Table 77. Lung Transplant Rejection Cellular Rejection , by Region USD Million (2025-2030)
  • Table 78. Lung Transplant Rejection Antibody-Mediated Rejections , by Region USD Million (2025-2030)
  • Table 79. Lung Transplant Rejection Allograft Rejection , by Region USD Million (2025-2030)
  • Table 80. Lung Transplant Rejection Acute Rejections , by Region USD Million (2025-2030)
  • Table 81. Lung Transplant Rejection Chronic Rejections , by Region USD Million (2025-2030)
  • Table 82. Lung Transplant Rejection: by Application(USD Million)
  • Table 83. Lung Transplant Rejection Lung Transplant Patients , by Region USD Million (2025-2030)
  • Table 84. South America Lung Transplant Rejection, by Country USD Million (2025-2030)
  • Table 85. South America Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 86. South America Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 87. Brazil Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 88. Brazil Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 89. Argentina Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 90. Argentina Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 91. Rest of South America Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 92. Rest of South America Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 93. Asia Pacific Lung Transplant Rejection, by Country USD Million (2025-2030)
  • Table 94. Asia Pacific Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 95. Asia Pacific Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 96. China Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 97. China Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 98. Japan Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 99. Japan Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 100. India Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 101. India Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 102. South Korea Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 103. South Korea Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 104. Taiwan Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 105. Taiwan Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 106. Australia Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 107. Australia Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 108. Rest of Asia-Pacific Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 110. Europe Lung Transplant Rejection, by Country USD Million (2025-2030)
  • Table 111. Europe Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 112. Europe Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 113. Germany Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 114. Germany Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 115. France Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 116. France Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 117. Italy Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 118. Italy Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 119. United Kingdom Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 120. United Kingdom Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 121. Netherlands Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 122. Netherlands Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 123. Rest of Europe Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 124. Rest of Europe Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 125. MEA Lung Transplant Rejection, by Country USD Million (2025-2030)
  • Table 126. MEA Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 127. MEA Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 128. Middle East Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 129. Middle East Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 130. Africa Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 131. Africa Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 132. North America Lung Transplant Rejection, by Country USD Million (2025-2030)
  • Table 133. North America Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 134. North America Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 135. United States Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 136. United States Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 137. Canada Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 138. Canada Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 139. Mexico Lung Transplant Rejection, by Type USD Million (2025-2030)
  • Table 140. Mexico Lung Transplant Rejection, by Application USD Million (2025-2030)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lung Transplant Rejection: by Type USD Million (2018-2023)
  • Figure 5. Global Lung Transplant Rejection: by Application USD Million (2018-2023)
  • Figure 6. South America Lung Transplant Rejection Share (%), by Country
  • Figure 7. Asia Pacific Lung Transplant Rejection Share (%), by Country
  • Figure 8. Europe Lung Transplant Rejection Share (%), by Country
  • Figure 9. MEA Lung Transplant Rejection Share (%), by Country
  • Figure 10. North America Lung Transplant Rejection Share (%), by Country
  • Figure 11. Global Lung Transplant Rejection share by Players 2023 (%)
  • Figure 12. Global Lung Transplant Rejection share by Players (Top 3) 2023(%)
  • Figure 13. Global Lung Transplant Rejection share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 16. AbbVie (United States) Revenue: by Geography 2023
  • Figure 17. Arthrex (United States) Revenue, Net Income and Gross profit
  • Figure 18. Arthrex (United States) Revenue: by Geography 2023
  • Figure 19. Zimmer Biomet (United States) Revenue, Net Income and Gross profit
  • Figure 20. Zimmer Biomet (United States) Revenue: by Geography 2023
  • Figure 21. Medtronic (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Medtronic (Ireland) Revenue: by Geography 2023
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 25. Stryker (United States) Revenue, Net Income and Gross profit
  • Figure 26. Stryker (United States) Revenue: by Geography 2023
  • Figure 27. BioLifeSolutions (United States) Revenue, Net Income and Gross profit
  • Figure 28. BioLifeSolutions (United States) Revenue: by Geography 2023
  • Figure 29. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 31. Veloxis Pharmaceuticals (Denmark) Revenue, Net Income and Gross profit
  • Figure 32. Veloxis Pharmaceuticals (Denmark) Revenue: by Geography 2023
  • Figure 33. Gleneagles global hospitals (India) Revenue, Net Income and Gross profit
  • Figure 34. Gleneagles global hospitals (India) Revenue: by Geography 2023
  • Figure 35. Global Lung Transplant Rejection: by Type USD Million (2025-2030)
  • Figure 36. Global Lung Transplant Rejection: by Application USD Million (2025-2030)
  • Figure 37. South America Lung Transplant Rejection Share (%), by Country
  • Figure 38. Asia Pacific Lung Transplant Rejection Share (%), by Country
  • Figure 39. Europe Lung Transplant Rejection Share (%), by Country
  • Figure 40. MEA Lung Transplant Rejection Share (%), by Country
  • Figure 41. North America Lung Transplant Rejection Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie (United States)
  • Arthrex (United States)
  • Zimmer Biomet (United States)
  • Medtronic (Ireland)
  • Novartis (Switzerland)
  • Stryker (United States)
  • BioLifeSolutions (United States)
  • Teva Pharmaceuticals (Israel)
  • Veloxis Pharmaceuticals (Denmark)
  • Gleneagles global hospitals (India)
Additional players considered in the study are as follows:
Pfizer Inc. (United States) , Allergan (Ireland) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 150 Pages 58 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lung Transplant Rejection Market Quantitative research analysis
Global Lung Transplant Rejection Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbVie (United States), Arthrex (United States), Zimmer Biomet (United States), Medtronic (Ireland), Novartis (Switzerland), Stryker (United States), BioLifeSolutions (United States), Teva Pharmaceuticals (Israel), Veloxis Pharmaceuticals (Denmark) and Gleneagles global hospitals (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increase in Chronic Rejection in Lung Transplant" is seen as one of major influencing trends for Lung Transplant Rejection Market during projected period 2023-2030.
The Lung Transplant Rejection market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Lung Transplant Rejection Market Report?

Have a Query? Click Here

Other Related Reports

Interventional Pulmonology Comprehensive Study by Type (Bronchoscopes, Electromagnetic Navigation Bronchoscopy Systems, Pleuroscopes, Respiratory Endotherapy Devices, Airway Stents, Pleural Catheters...
$ 3750
Biopreservation Comprehensive Study by Type (Biopreservation Media, Biopreservation Equipment, Others), Application (Biobanking, Regenerative Medicine, Drug Discovery, Others), End Users (Biobanks, H...
$ 3800
Chromatography Based Cannabis Comprehensive Study by Type (High-Performance Liquid Chromatography, Gas Chromatography, Supercritical Fluid Chromatography, Thin Layer Chromatography), Application (Pai...
$ 3350
Pathological Examination Comprehensive Study by Type (Traditional Pathology, Digital Pathology), Application (Digestive Organs, Other), Testing Services (Anatomic Pathology, Surgical Pathology, Cytop...
$ 3350
HIV-AIDS Diagnostics Comprehensive Study by Type (Assay, Kit, Reagent, Instrument, Software, Services, Others), Application (Diagnostic Laboratories, Hospitals, Blood Banks, Home Care Settings, Other...
$ 3350
Healthcare Contract Research Outsourcing Comprehensive Study by Service (Clinical Trial Service, Regulatory Service, Clinical Data Management & Biometrics, Medical Writing, Site Management Protocol, ...
$ 3750